Arvinas rises after US FDA approves Pfizer, co's breast cancer drug

Arvinas

01/05/2026 18:08

** Shares of Arvinas ARVN.O rise 3.7% to $10.27

** The U.S. Food and Drug Administration approved Pfizer PFE.N and Arvinas' breast cancer drug, regulator says

** Pfizer's shares down 1.1% at $26.4

** The drug, branded Veppanu, is approved for certain advanced breast cancer patients

** The FDA also approved companion diagnostic device, Guardant360 CDx, to identify patients with ESR1 mutations for treatment

** Including session moves, ARVN down 13.4% YTD

 (Reporting by Siddhi Mahatole)

 ((siddhi.mahatole@thomsonreuters.com))